| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Bz-RS-iSer(3-Ph)-OMe targets multiple cellular processes including HSV replication, cell mitosis, and immune cell proliferation. As a paclitaxel derivative, it may interact with microtubules and affect mitotic spindle function, leading to cell cycle arrest. The compound inhibits HSV replication cycle at low cytotoxicity, blocks Vero cell mitosis, affects M-MSV-induced tumor size, and inhibits PHA-induced T lymphocyte proliferation, affecting immune responses.
|
|---|---|
| ln Vitro |
Bz-RS-iSer(3-Ph)-OMe demonstrates in vitro activity as a paclitaxel derivative. It inhibits HSV replication cycle at low cytotoxicity and blocks Vero cell mitosis. The compound affects M-MSV-induced tumor size and inhibits PHA-induced T lymphocyte proliferation, affecting immune responses. Its activity is typically assessed in antiviral assays measuring HSV replication, cell cycle analysis for mitotic blockade, and T cell proliferation assays.
|
| ln Vivo |
In vivo studies for Bz-RS-iSer(3-Ph)-OMe have not been extensively documented in the available literature. As an intermediate in taxane synthesis, its in vivo effects are typically studied in the context of paclitaxel derivatives. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound affects M-MSV-induced tumor size, suggesting potential antitumor activity.
|
| Enzyme Assay |
For antiviral activity assays, Bz-RS-iSer(3-Ph)-OMe is tested against HSV at various concentrations. Viral replication is assessed by measuring viral titers or cytopathic effect. Cytotoxicity is assessed in parallel using standard cell viability assays. For cell cycle analysis, Vero cells are treated with the compound and cell cycle distribution is analyzed by flow cytometry. For T cell proliferation assays, PHA-stimulated T lymphocytes are treated with the compound and proliferation is measured by [3H]-thymidine incorporation.
|
| Cell Assay |
For cellular studies, Vero cells or other appropriate cell lines are cultured in appropriate media and treated with Bz-RS-iSer(3-Ph)-OMe at various concentrations. Cell viability is assessed using MTT assays to determine cytotoxicity. Cell cycle analysis is performed using propidium iodide staining and flow cytometry to assess mitotic blockade. For T cell studies, PHA-stimulated T lymphocytes are treated with the compound and proliferation is measured.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of HSV infection or M-MSV-induced tumors would be used. Bz-RS-iSer(3-Ph)-OMe would be administered via appropriate routes at various doses. Tumor size would be measured, and viral load would be assessed. Immune responses would be evaluated by measuring T cell proliferation. However, detailed in vivo protocols for Bz-RS-iSer(3-Ph)-OMe have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Bz-RS-iSer(3-Ph)-OMe have not been fully characterized in the available literature. The compound has a molecular formula of C17H17NO4 and a molecular weight of 299.32. Purity is 98%. It is an intermediate in taxane synthesis. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed to fully understand its ADME properties.
|
| Toxicity/Toxicokinetics |
Bz-RS-iSer(3-Ph)-OMe is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a paclitaxel derivative and intermediate in taxane synthesis, it inhibits HSV replication, blocks mitosis, and affects immune responses. Standard laboratory safety precautions should be followed when handling this compound. Purity 98%.
|
| References |
[1]. Krawczyk E, et al. Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'
|
| Additional Infomation |
Bz-RS-ISer(3-Ph)-Ome is a fatty acid ester.
Bz-RS-iSer(3-Ph)-OMe is an intermediate in taxane synthesis with molecular formula C17H17NO4 and molecular weight 299.32. It is a paclitaxel derivative that inhibits HSV replication at low cytotoxicity, blocks Vero cell mitosis, affects M-MSV-induced tumor size, and inhibits PHA-induced T lymphocyte proliferation. It is for research use only and has not been approved for clinical applications. Purity 98%. |
| Molecular Formula |
C17H17NO4
|
|---|---|
| Molecular Weight |
299.32
|
| Exact Mass |
299.115
|
| CAS # |
32981-85-4
|
| PubChem CID |
182104
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
540.3±50.0 °C at 760 mmHg
|
| Flash Point |
280.6±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
373
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O([H])C([H])(C(=O)OC([H])([H])[H])[C@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(C1C([H])=C([H])C([H])=C([H])C=1[H])=O
|
| InChi Key |
UYJLJICUXJPKTB-LSDHHAIUSA-N
|
| InChi Code |
InChI=1S/C17H17NO4/c1-22-17(21)15(19)14(12-8-4-2-5-9-12)18-16(20)13-10-6-3-7-11-13/h2-11,14-15,19H,1H3,(H,18,20)/t14-,15+/m0/s1
|
| Chemical Name |
methyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (417.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (7.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (7.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
